Ssris in the treatment of obsessive-compulsive disorder

Charles Cartwright, Eric Hollander

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The introduction of the SSRIs (selective serotonin reuptake inhibitors) over the past decade has provided exciting new opportunities for the treatment of obsessive-compulsive disorder (OCD). The serotonin hypothesis, based on the preferential response of OCD to the serotonin reuptake inhibitor, clomipramine, paved the way for research into the efficacy of the SSRIs in the treatment of this disorder. Large, controlled, multicenter studies have found clomipramine and the SSRIs, fluoxetine, fluvoxamine, sertraline, and paroxetine, to be effective and safe in the treatment of OCD. Meta-analytic studies have reported that clomipramine is superior to the SSRIs; however, direct head-to-head comparisons suggest equal efficacy. As SSRIs have a more favorable side-effect profile they may be preferable as first-line treatment of OCD. Improvement following adequate OCD drug treatment is frequently partial whereupon augmentation strategies may become necessary. High rates of relapse have been reported on discontinuation of SRI treatment. Long-term maintenance treatment has been found to be effective in sustaining initial therapeutic gains and bringing about further improvement.

Original languageEnglish (US)
Pages (from-to)105-113
Number of pages9
JournalDepression and Anxiety
Volume8
Issue numberSUPPL. 1
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Obsessive-Compulsive Disorder
Serotonin Uptake Inhibitors
Clomipramine
Fluvoxamine
Sertraline
Paroxetine
Fluoxetine
Multicenter Studies
Serotonin
Recurrence
Research
Pharmaceutical Preparations

Keywords

  • Clomipramine
  • Fluoxetine
  • Fluvoxamine
  • Obsessive- compulsive disorder
  • Paroxetine
  • Sertraline
  • SSRIs

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)
  • Clinical Psychology

Cite this

Ssris in the treatment of obsessive-compulsive disorder. / Cartwright, Charles; Hollander, Eric.

In: Depression and Anxiety, Vol. 8, No. SUPPL. 1, 1998, p. 105-113.

Research output: Contribution to journalArticle

Cartwright, Charles ; Hollander, Eric. / Ssris in the treatment of obsessive-compulsive disorder. In: Depression and Anxiety. 1998 ; Vol. 8, No. SUPPL. 1. pp. 105-113.
@article{356dd810eb0745568ef4fe0be191b8fb,
title = "Ssris in the treatment of obsessive-compulsive disorder",
abstract = "The introduction of the SSRIs (selective serotonin reuptake inhibitors) over the past decade has provided exciting new opportunities for the treatment of obsessive-compulsive disorder (OCD). The serotonin hypothesis, based on the preferential response of OCD to the serotonin reuptake inhibitor, clomipramine, paved the way for research into the efficacy of the SSRIs in the treatment of this disorder. Large, controlled, multicenter studies have found clomipramine and the SSRIs, fluoxetine, fluvoxamine, sertraline, and paroxetine, to be effective and safe in the treatment of OCD. Meta-analytic studies have reported that clomipramine is superior to the SSRIs; however, direct head-to-head comparisons suggest equal efficacy. As SSRIs have a more favorable side-effect profile they may be preferable as first-line treatment of OCD. Improvement following adequate OCD drug treatment is frequently partial whereupon augmentation strategies may become necessary. High rates of relapse have been reported on discontinuation of SRI treatment. Long-term maintenance treatment has been found to be effective in sustaining initial therapeutic gains and bringing about further improvement.",
keywords = "Clomipramine, Fluoxetine, Fluvoxamine, Obsessive- compulsive disorder, Paroxetine, Sertraline, SSRIs",
author = "Charles Cartwright and Eric Hollander",
year = "1998",
doi = "10.1002/(SICI)1520-6394(1998)8:1+<105::AID-DA16>3.0.CO;2-T",
language = "English (US)",
volume = "8",
pages = "105--113",
journal = "Depression and Anxiety",
issn = "1091-4269",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Ssris in the treatment of obsessive-compulsive disorder

AU - Cartwright, Charles

AU - Hollander, Eric

PY - 1998

Y1 - 1998

N2 - The introduction of the SSRIs (selective serotonin reuptake inhibitors) over the past decade has provided exciting new opportunities for the treatment of obsessive-compulsive disorder (OCD). The serotonin hypothesis, based on the preferential response of OCD to the serotonin reuptake inhibitor, clomipramine, paved the way for research into the efficacy of the SSRIs in the treatment of this disorder. Large, controlled, multicenter studies have found clomipramine and the SSRIs, fluoxetine, fluvoxamine, sertraline, and paroxetine, to be effective and safe in the treatment of OCD. Meta-analytic studies have reported that clomipramine is superior to the SSRIs; however, direct head-to-head comparisons suggest equal efficacy. As SSRIs have a more favorable side-effect profile they may be preferable as first-line treatment of OCD. Improvement following adequate OCD drug treatment is frequently partial whereupon augmentation strategies may become necessary. High rates of relapse have been reported on discontinuation of SRI treatment. Long-term maintenance treatment has been found to be effective in sustaining initial therapeutic gains and bringing about further improvement.

AB - The introduction of the SSRIs (selective serotonin reuptake inhibitors) over the past decade has provided exciting new opportunities for the treatment of obsessive-compulsive disorder (OCD). The serotonin hypothesis, based on the preferential response of OCD to the serotonin reuptake inhibitor, clomipramine, paved the way for research into the efficacy of the SSRIs in the treatment of this disorder. Large, controlled, multicenter studies have found clomipramine and the SSRIs, fluoxetine, fluvoxamine, sertraline, and paroxetine, to be effective and safe in the treatment of OCD. Meta-analytic studies have reported that clomipramine is superior to the SSRIs; however, direct head-to-head comparisons suggest equal efficacy. As SSRIs have a more favorable side-effect profile they may be preferable as first-line treatment of OCD. Improvement following adequate OCD drug treatment is frequently partial whereupon augmentation strategies may become necessary. High rates of relapse have been reported on discontinuation of SRI treatment. Long-term maintenance treatment has been found to be effective in sustaining initial therapeutic gains and bringing about further improvement.

KW - Clomipramine

KW - Fluoxetine

KW - Fluvoxamine

KW - Obsessive- compulsive disorder

KW - Paroxetine

KW - Sertraline

KW - SSRIs

UR - http://www.scopus.com/inward/record.url?scp=0031788537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031788537&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1520-6394(1998)8:1+<105::AID-DA16>3.0.CO;2-T

DO - 10.1002/(SICI)1520-6394(1998)8:1+<105::AID-DA16>3.0.CO;2-T

M3 - Article

C2 - 9809222

AN - SCOPUS:0031788537

VL - 8

SP - 105

EP - 113

JO - Depression and Anxiety

JF - Depression and Anxiety

SN - 1091-4269

IS - SUPPL. 1

ER -